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Hepatitis B virus (HBV) infection is an important issue for infectious control in dialysis 
hospitals. Occult HBV infection (OBI) is defined as the presence of HBV genome in serum or 
liver tissue without detectable hepatitis B surface antigen (HBsAg). The prevalence of OBI in 
Japanese chronic hemodialysis patients was 0.3% in previous report (1). They were isolated 
anti-hepatitis B core antibody (anti-HBc) pattern; negative anti-hepatitis B surface antibody 
(HBsAb) and positive anti-HBc, and detected serum HBV-DNA under quantitative sensitivity: 
2.1 Log copies/mL (20 IU/mL). We herein report an OBI patient under dialysis with increased 
serum HBV-DNA level. 
 
CASE REPORT 
An 86-year-old female initiated hemodialysis 6 years ago due to end-stage kidney disease 
caused by nephrosclerosis. She was affected with colon cancer in 65 years old and lung cancer 
in 84 years old, and they were treated with complete resection. She did not need chemotherapy 
nor radiation therapy, and she has never received blood transfusion in her life. She transferred 
to our hospital 4 years ago. In the infectious screening tests, HBsAg, HBsAb, anti-hepatitis C 
virus antibody, anti-human immunodeficiency virus antibody were negative and anti-HBc was 
positive with low level (10.2 S/CO). Aspartate aminotransferase (AST) and alanine 
aminotransferase (ALT) were 13 U/L and 6 U/L, respectively. Computed tomography and 
ultrasonography showed almost normal images. Her liver findings have kept almost normal. 
Because the number of hemodialysis patients in our hospital exceeded 300 and the prevalence 
of OBI is 0.3%, we checked serum HBV-DNA by real-time polymerase chain reaction (PCR) test 
for the patients with positive for HBsAb or anti-HBc. In the HBsAg negative patient group, 
HBV-DNA was not detected except for her. Her HBV-DNA level was 2.6 Log copies/mL (68 
IU/mL). She has continued hemodialysis without any symptoms and abnormal laboratory tests 
for 6 months after OBI diagnosis. To prevent horizontal HBV transmission in hospital, we 
fixed her bed and console, and keep routine check for viral infections. 
 
DISCUSSION 
The serological pattern of OBI includes cases of acute HBV infection in the window period 
and HBV reactivation in immunosuppressive therapy, which lead to severe hepatitis. Because 
our patient has never had hepatitis findings, she was supposed to get infected in the old days. 
In general, after disappearance of HBsAg, HBsAb persists for life and confers long-term 
immunity. Interestingly, as far as we know, all reported HD patients of OBI were negative for 
HBsAb (1–3) and most of them were isolated anti-HBc pattern. We speculate that impaired 
immune system of chronic HD patients might contribute to negative HBsAb, which allowed 
HBV to replicate.  
Routine blood vessel punctures and extracorporeal circulation are risk factors for horizontal 
transmission. The degree of transmission risk depends on the DNA level of infected patient. 
Even though our patient remained low DNA level, it would speculate that HBV-DNA level in 
chronic HD patients could increase over quantitative PCR sensitivity. With regard to infectious 
control, the screening of HBV-DNA should be implemented for HD patients (4). Limiting the 
patients with isolated anti-HBc pattern may be considered reasonable. We should recognize 
the presence of OBI patients under dialysis. 
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